Clinical trials: AdV Infection
Adenocarcinoma of the Prostate
First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients.
This open label, dose escalating study is a phase I/IIa first in man study designed to evaluate the safety and tolerability of intratumoral administration of a novel oncolytic adenovirus (ORCA-010) in treating diagnosed treatment…
- Trial name
- NCT04097002
- Testing
- ORCA-010
- Where
- 5 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Orca Therapeutics B.V.
Viral Infection
ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus
The subjects eligible for this trial have a type of blood cell cancer, other blood disease or a genetic disease for which they will receive a stem cell transplant.
- Trial name
- ARMS (NCT01570283)
- Testing
- Multivirus-specific T cells Dose Level 1, Multivirus-specific T cells Dose Level 2, Multivirus-specific T cells Dose Level 3
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- AlloVir
Rotavirus Infection, Adenoviridae Infection
Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Enteric Viruses in Children
The purpose of this study is to determine the effect of nitazoxanide suspension in treating diarrhea caused by enteric viruses in children less than 12 years of age.
- Conditions
- Rotavirus Infection, Adenoviridae Infection, Norovirus Infection
- Trial name
- NCT00302640
- Testing
- Alinia (nitazoxanide)
- Volunteers
- 50 people
- Sponsor
- Romark Laboratories L.C.
Viral Conjunctivitis
ADenoVirus Initiative Study in Epidemiology in France
The objectives of this study is to assess the characteristics and frequency of adenovirus conjunctivitis in a population of male and female patients from one year of age who present signs and symptoms of acute conjunctivitis.
- Trial name
- NCT02054234
- Where
- 19 sites in France
- Volunteers
- 357 people
- Sponsor
- NicOx
Respiratory Syncytial Viruses, Lower Respiratory Tract Disease
A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older
The study will enroll up to 27,200 participants in order to demonstrate the efficacy of the active Ad26.RSV.preF-based study vaccine in the prevention of Reverse Transcription Polymerase Chain Reaction (RT-PCR) confirmed…
- Trial name
- EVERGREEN (NCT04908683)
- Testing
- Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF
- Where
- 272 sites in United States, Australia and 12 more
- Volunteers
- 25,236 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Adenovirus Infections
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
This randomized, open-label, parallel group, two-arm, multi-center assessment will compare IV BCV with IV CDV in adult and pediatric allogeneic HCT recipients with AdV viremia.
- Trial name
- ENOVIA (NCT07387367)
- Testing
- cidofovir, Brincidofovir
- Where
- 81 sites in United States, Austria and 11 more
- Volunteers
- 180 people
- Sponsor
- SymBio Pharmaceuticals
Hepatitis B, Healthy
First in Human Study of ChAdOx1-HBV in Healthy Participants and Participants With Chronic hepB Infection
This is a Phase 1, first in human study of ChAdOx1-HBV. The study will be conducted in 40 healthy participants and 12 participants with CHB and virally suppressed with oral antiviral medication.
- Trial name
- NCT04297917
- Testing
- ChAdOx1-HBV
- Where
- 4 sites in United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Barinthus Biotherapeutics
Metastatic Cancer, Epithelial Tumor
First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)
This study will evaluate the safety, tolerability and preliminary efficacy and also pharmacokinetics, immunogenicity and other pharmacodynamic effects to elucidate the mechanism of action of NG-350A, either alone or in…
- Trial name
- FORTITUDE (NCT03852511)
- Testing
- NG-350A
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- Akamis Bio
Corona Virus Infection
BBV152/BBV154 Heterologus Prime-Boost Study
All participants will be assessed for immunogenicity and safety endpoints and provide a blood sample before the administration of the first dose of IP.
- Trial name
- BBV152BBV154 (NCT05639998)
- Testing
- COVAXIN(BBV152), BBV154 Intranasal Vaccine
- Where
- 11 sites in India
- Volunteers
- 608 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
Adenoviral Infection
A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047
PXVX0047 (Adenovirus Type 4 and Type 7 Vaccine [A549 Cells], Live, Oral) is an investigational vaccine in development for the indication of active immunization against adenovirus infection.
- Trial name
- NCT03160339
- Testing
- PXVX0047 Vaccine, Teva Ad4/Ad7 Vaccine
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
COVID-19
A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
This study is a randomized, double-blind, placebo -controlled IIb clinical trial, in order to evaluate the safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in people 6 years old and…
- Trial name
- NCT04566770
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Viral Conjunctivitis
ADenoVirus Initiative Study in Epidemiology in Germany
The objectives of this study is to assess the characteristics and frequency of adenovirus conjunctivitis in a population of male and female patients from one year of age who present signs and symptoms of acute conjunctivitis.
- Trial name
- NCT02054273
- Where
- 13 sites in Germany
- Volunteers
- 240 people
- Sponsor
- NicOx
Bird Flu, Influenza
Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1
The purpose of this study is to compare the safety and immunogenicity over a 9-month period of five different dosages of Ad4-H5-Vtn in volunteers (Vaccinees) who receive three doses of the study vaccine or placebo.
- Trial name
- NCT01006798
- Testing
- Ad4-H5-Vtn, Sanofi Pasteur Influenza Virus Vaccine, H5N1
- Where
- 4 sites in United States
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Adenovirus Infection
Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A)
Patients enrolled on this study will have received a stem cell transplant. After a transplant, while the immune system grows back the patient is at risk for infection.
- Trial name
- NCT02276820
- Testing
- Viralym-A
- Where
- 2 sites in United States
- Sponsor
- AlloVir
Adenovirus
A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304
The objective is data collection to determine background rates of adenovirus (AdV) progression and mortality in subjects with Adenovirus (AdV) infection and/or disease.
- Trial name
- NCT02420080
- Testing
- Brincidofovir
- Where
- 22 sites in United States
- Volunteers
- 100 people
- Sponsor
- Jazz Pharmaceuticals
Bladder Cancer, High Grade
Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer
This is an expanded access protocol to study the safety and efficacy of CG0070 in Cis and Cis with Ta and/or T1 disease patients who failed both BCG therapy and the BOND protocol (NCT 01438112), or in high grade Ta and T1…
- Conditions
- Bladder Cancer, High Grade, Non Muscle Invasive
- Trial name
- exBOND (NCT02143804)
- Testing
- oncolytic adenovirus expressing GMCSF
- Where
- United States
- Sponsor
- CG Oncology, Inc.
Influenza
A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine
A Phase 2 Randomized, Placebo- and Active-Controlled, Human Influenza A/California/04/2009 (H1N1) Challenge Study Following Administration of an Oral H1N1 Hemagglutinin (HA) Adenoviral-Vector Based Seasonal Influenza Vaccine and…
- Trial name
- NCT02918006
- Testing
- VXA-A1.1, Fluzone®
- Where
- United States
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Vaxart
Adenovirus
The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation
This study was designed to assess the safety, overall tolerability, and antiviral activity of "short course" brincidofovir (BCV) therapy, as compared with current standard of care (SoC), for the treatment of adenovirus (AdV)…
- Trial name
- AdAPT (NCT03339401)
- Testing
- Standard of Care, Brincidofovir
- Where
- 36 sites in United States, France and 7 more
- Volunteers
- 29 people
- Sponsor
- Jazz Pharmaceuticals
Respiratory Viral Illnesses: Influenza A/B, RSV, Adenovirus
Residual Sample Collection for Respiratory Viral Panel
Collect de-identified, residual samples to support a clinical trial. Samples may be prospectively or retrospectively collected. Overall Study Objective Obtain clinical performance data to characterize clinical performance of the…
- Trial name
- NCT02049918
- Where
- United States
- Volunteers
- 1,487 people
- Sponsor
- GenMark Diagnostics
Virus Diseases
A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children
The purpose of this study is to assess the safety and reactogenicity of a single IM dose of the GSK3390107A (ChAd3 EBO-Z) vaccine, overall and in children aged 1 to 5, 6 to 12, and 13 to 17 years, separately.
- Trial name
- NCT02548078
- Testing
- GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A), Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine
- Where
- 2 sites in Mali, Senegal
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline